COMP <GO>
CNMD vs UNH // REVENUE GROWTH (YOY)
CONMED Corporation (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CNMD 4
— UNH 8
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $44.29 (-3.13%) • MKT CAP: $1.36B
revenue-growth
5.20%
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 88.57% | -33.97 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 11.47% | -3.67 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 16.4x | -5.05 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | 6.48% | +4.59 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | 4.82% | +2.68 | CNMD | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 3.14% | +0.26 | CNMD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.20% | 6.46% | -1.26 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.82% | 2.28% | -0.46 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 3.12 | -1.21 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.1 | 59.2 | -12.10 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 17.7x | +9.16 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $368.83B | -$367.47B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | UNH REV | CNMD GROSS % | UNH GROSS % | CNMD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $447.57B | 54.6% | 88.7% | $150.9M | $16.07B |
| FY 2024 | $1.31B | $400.28B | 56.1% | 88.3% | $153.9M | $20.70B |
| FY 2023 | $1.24B | $371.62B | — | 89.6% | $125.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
UNH // BETA 0.33